Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial
Olöf Bjarnadottir(Lund University), Signe Borgquist(Aarhus University), Karin Jirström(Lund University), Mathias Uhlén(Science for Life Laboratory), Lisa Rydén(Lund University), Carsten Rose(Lund University), Dorthe Grabau(Lund University), Quinci Romero(Lund University), Niklas Loman(Lund University), Pär‐Ola Bendahl(Lund University), Henrik Johannesson(AlbaNova)
Cited by 236
Related Papers
Average Risks of Breast and Ovarian Cancer Associated with BRCA1 or BRCA2 Mutations Detected in Case Series Unselected for Family History: A Combined Analysis of 22 Studies
|The American Journal of Human Genetics|2003|3.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
|The Lancet|2010|2.3k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
How many human proteoforms are there?
|Nature Chemical Biology|2018|945